Tissue-specific expression of SV40 in tumors associated with the Li–Fraumeni syndrome

Association of SV40 with human tumors

“…David Malkin (University of Toronto, Canada) reported that SV40 was present in tumors from two patients with Li-Fraumeni syndrome (Malkin et al, 2001). In a Li-Frameni family proband with both an embryonal rhabdomyosarcoma (RMS) and a choroid plexus carcinoma (CPC), a mutant p53 allele was reduced to homozygosity in the RMS.…”

SV40 in human brain cancers and non-Hodgkin's lymphoma

“…In all, 11 studies fulfilled the criteria among 16 articles reporting on SV40 and primary human brain cancers through November 2001 (Figure 1) (Weiss et al, 1975;Meinke et al, 1979;Krieg et al, 1981;Ibelgaufts and Jones, 1982;Dorries et al, 1987;Bergsagel et al, 1992;Martini et al, 1996;Suzuki et al, 1997;Zhen et al, 1999;Weggen et al, 2000;Malkin et al, 2001). The adjusted combined effect size (odds ratio (OR)) of the 11 original studies was 3.9 (95% confidence interval (CI), 6-8).…”

“…The history of SV40 and its role in the development of primary brain cancers began soon after its discovery in 1960 when it was demonstrated to induce central nervous system malignancies following injection into newborn hamsters (Eddy et al, 1962;Girardi et al, 1962). Human studies conducted in the 1970s and 1980s identified SV40-positive brain tumors using DNA hybridization techniques or indirect immunofluorescence for viral proteins (Weiss et al, 1975;Tabuchi et al, 1978;Meinke et al, 1979;Krieg et al, 1981;Ibelgaufts and Jones, 1982;Dorries et al, 1987), whereas studies performed in the 1990s and 2000s generally used PCR-based approaches (Bergsagel et al, 1992;Martini et al, 1996;Suzuki et al, 1997;Huang et al, 1999;Krynska et al, 1999;Zhen et al, 1999;Ohgaki et al, 2000;Weggen et al, 2000;Kouhata et al, 2001;Malkin et al, 2001;Engels et al, 2002;Martini et al, 2002).…”

“…The effect (OR) was based on a total of 1003 samples, of which 589 were primary brain cancer samples and 414 were control samples. Five studies assessed the presence of SV40 in brain cancers by initial PCR (Bergsagel et al, 1992;Martini et al, 1996;Suzuki et al, 1997;Weggen et al, 2000;Malkin et al, 2001), four by DNA hybridization techniques (Meinke et al, 1979;Krieg et al, 1981;Ibelgaufts and Jones, 1982;Dorries et al, 1987), one by indirect immunofluorescence (Weiss et al, 1975), and one by immunoprecipitation (Zhen et al, 1999). Seven studies included only noncancer control samples (Meinke et al, 1979;Krieg et al, 1981;Dorries et al, 1987;Martini et al, 1996;Suzuki et al, 1997;Zhen et al, 1999;Malkin et al, 2001), and four studies included both noncancer and cancer control samples (Weiss et al, 1975;Ibelgaufts and Jones, 1982;Bergsagel et al, 1992;Weggen et al, 2000).…”

“…Seven studies included only noncancer control samples (Meinke et al, 1979;Krieg et al, 1981;Dorries et al, 1987;Martini et al, 1996;Suzuki et al, 1997;Zhen et al, 1999;Malkin et al, 2001), and four studies included both noncancer and cancer control samples (Weiss et al, 1975;Ibelgaufts and Jones, 1982;Bergsagel et al, 1992;Weggen et al, 2000). Of the studies in which SV40 was detected in primary human brain cancers, 80% had performed a second analysis using a different molecular biology technique that confirmed the initial result (Krieg et al, 1981;Dorries et al, 1987;Bergsagel et al, 1992;Martini et al, 1996;Suzuki et al, 1997;Zhen et al, 1999;Weggen et al, 2000;Malkin et al, 2001). In addition, the systematic assessment of the molecular biology data conclusively established that SV40 is significantly associated with primary bone cancers (OR, 25.0; 95% CI, 6.8-88) and malignant mesotheliomas (OR, 17; 95% CI, 10-28 Vilchez et al, 2003a).…”